(NewsDirect)
Valeo Pharma CEO Steve Saviuk joinedSteve Darling from Proactive to share news the company had a recordquarter in the three months to January 31, 2023, with revenue of $13.2million, up 210% over 1Q 2022.
Saviuk tells Proactive this marks the 5th consecutive quarter ofgrowth for the company, with adjusted gross profit increasing by 178%to $4.2 million from a year earlier.
Physicians prescribingEnerzair and Atectura reached 1,583 at the end of the first quarter,39% growth for the quarter and a 799% increase year-over-year. Totalannual Enerzair and Atectura prescriptions surpassed 34,000 at the endof 1Q 2023, up 1,917% year-over-year.
ContactDetails
Proactive Canada
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.